iNK cells

DRUG2 trials

Sponsors

Guangzhou Ruixin Biotechnological Co., LTD

Conditions

Acute Myeloid Leukemia (AML)Small Cell Lung Cancer

Early Phase 1

Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia

Not yet recruitingNCT06702098

Guangzhou Ruixin Biotechnological Co., LTDAcute Myeloid Leukemia (AML)

Start: 2024-11-25End: 2026-11-24Target: 10Updated: 2024-11-22

INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer

Enrolling by invitationNCT06747832

Guangzhou Ruixin Biotechnological Co., LTDSmall Cell Lung Cancer

Start: 2024-12-15End: 2026-12-14Target: 10Updated: 2024-12-24